We demonstrated that the addition of HER2 immunogenic sequences to the minor coat protein III (pIII) of M13 phage particles breaks tolerance against HER2 self-protein and elicits protective anti-cancer immune responses when administered before tumor onset in ∆16HER2 transgenic mice. Here, ERBB2 is linked to cancer.